US RAC REVIEW QUESTIONS RAPS MODULES
ACTUAL EXAM QUESTIONS AND ANSWERS
LATEST UPDATE 2025/2026 NEW
As a regulatory affairs professional, you are responsible for developing the
content of an information package for a Type B meeting with FDA. Your
primary objective is to:
A) Reach consensus on content from contributing team members
B) Ensure content is sufficient to support meeting objective(s) and questions to
FDA
C) Provide appropriate preclinical summary
D) Provide appropriate clinical summary --CORRECT ANSWER--B) Ensure
content is sufficient to support meeting objective(s) and questions to FDA
You, a regulatory affairs professional, are assessing the information to be
submitted in support of a marketing application for a new dosage form for a
listed drug. You lack right of reference to one key preclinical report. Which
type of application will you prepare for submission?
A) 505 (b) (1)
B) 505 (b) (2)
C) 505 (j)
D) PMA --CORRECT ANSWER--B) 505 (b) (2)
Page 1 of 37
,If FDA were to invoke the Application Integrity Policy, which of the following
is a possible outcome?
A) Defer review of pending application(s)
B) "File" a marketing application at the 60 day review
C) Grant a waiver or deferral for pediatric clinical study
D) Approve a marketing application --CORRECT ANSWER--A) Defer review
of pending application(s)
Which of the following supplements to an approved NDA/BLA must be
approved by FDA prior to distributing product made using the change?
A) Make change(s) to comply with USP
B) Change in the technical grade of an excipient, same
specifications and use
C) Add a warning statement to prescribing information
D) Process change outside the validated range --CORRECT ANSWER--D)
Process change outside the validated range
Which of the following products would not be regulated by CDER?
A) Therapeutic proteins
Page 2 of 37
,B) Vaccines
C) Chemically synthesized small molecules
D) Monoclonal antibodies --CORRECT ANSWER--B) Vaccines
In which situation is an IND not required?
A) You intend to conduct a clinical trial with an investigational new drug
B) You intend to conduct a clinical trial with an approved drug to support a
marketing application for a new indication
C) You intend to collect blood samples from subjects to look for biomarkers or
pharmacogenetic information
D) You intend to conduct a clinical trial using 2 of your approved drugs in a
new combination --CORRECT ANSWER--C) You intend to collect blood
samples from subjects to look for biomarkers or pharmacogenetic information
In the clinical development plan for an investigational antihypertensive drug,
which of the following studies would typically be conducted first:
A) 1 month repeat dose toxicology study
B) Single dose escalation PK study in healthy volunteers
C) Multiple dose PK study in healthy volunteers
D) Single dose escalation study in hypertensive patients --CORRECT
ANSWER--B) Single dose escalation PK study in healthy volunteers
Page 3 of 37
, A sponsor must report an unexpected, fatal or life-threatening experience
believed to be associated with an unapproved drug/biologic:
A) to FDA, investigators and IRBs within 7 calendar days
B) to FDA and investigators within 7 calendar days
C) to FDA within 14 calendar days
D) to FDA and investigators within 7 working days --CORRECT ANSWER--
B) to FDA and investigators within 7 calendar days
Which of the following is a covered study as defined under Financial Disclosure
regulations:
A) Phase I dose escalation study
B) Phase I/II Pharmacokinetic Study
C) A large open label safety study conducted at a large number of study sites
D) Phase III pivotal study --CORRECT ANSWER--D) Phase III pivotal study
Your company is developing a product to treat a serious and life threatening
disease. A clinically meaningful, well established primary endpoint will be used
in the pivotal studies. Which regulatory strategy might you select prior to
commencing Phase 3 studies?
Page 4 of 37
ACTUAL EXAM QUESTIONS AND ANSWERS
LATEST UPDATE 2025/2026 NEW
As a regulatory affairs professional, you are responsible for developing the
content of an information package for a Type B meeting with FDA. Your
primary objective is to:
A) Reach consensus on content from contributing team members
B) Ensure content is sufficient to support meeting objective(s) and questions to
FDA
C) Provide appropriate preclinical summary
D) Provide appropriate clinical summary --CORRECT ANSWER--B) Ensure
content is sufficient to support meeting objective(s) and questions to FDA
You, a regulatory affairs professional, are assessing the information to be
submitted in support of a marketing application for a new dosage form for a
listed drug. You lack right of reference to one key preclinical report. Which
type of application will you prepare for submission?
A) 505 (b) (1)
B) 505 (b) (2)
C) 505 (j)
D) PMA --CORRECT ANSWER--B) 505 (b) (2)
Page 1 of 37
,If FDA were to invoke the Application Integrity Policy, which of the following
is a possible outcome?
A) Defer review of pending application(s)
B) "File" a marketing application at the 60 day review
C) Grant a waiver or deferral for pediatric clinical study
D) Approve a marketing application --CORRECT ANSWER--A) Defer review
of pending application(s)
Which of the following supplements to an approved NDA/BLA must be
approved by FDA prior to distributing product made using the change?
A) Make change(s) to comply with USP
B) Change in the technical grade of an excipient, same
specifications and use
C) Add a warning statement to prescribing information
D) Process change outside the validated range --CORRECT ANSWER--D)
Process change outside the validated range
Which of the following products would not be regulated by CDER?
A) Therapeutic proteins
Page 2 of 37
,B) Vaccines
C) Chemically synthesized small molecules
D) Monoclonal antibodies --CORRECT ANSWER--B) Vaccines
In which situation is an IND not required?
A) You intend to conduct a clinical trial with an investigational new drug
B) You intend to conduct a clinical trial with an approved drug to support a
marketing application for a new indication
C) You intend to collect blood samples from subjects to look for biomarkers or
pharmacogenetic information
D) You intend to conduct a clinical trial using 2 of your approved drugs in a
new combination --CORRECT ANSWER--C) You intend to collect blood
samples from subjects to look for biomarkers or pharmacogenetic information
In the clinical development plan for an investigational antihypertensive drug,
which of the following studies would typically be conducted first:
A) 1 month repeat dose toxicology study
B) Single dose escalation PK study in healthy volunteers
C) Multiple dose PK study in healthy volunteers
D) Single dose escalation study in hypertensive patients --CORRECT
ANSWER--B) Single dose escalation PK study in healthy volunteers
Page 3 of 37
, A sponsor must report an unexpected, fatal or life-threatening experience
believed to be associated with an unapproved drug/biologic:
A) to FDA, investigators and IRBs within 7 calendar days
B) to FDA and investigators within 7 calendar days
C) to FDA within 14 calendar days
D) to FDA and investigators within 7 working days --CORRECT ANSWER--
B) to FDA and investigators within 7 calendar days
Which of the following is a covered study as defined under Financial Disclosure
regulations:
A) Phase I dose escalation study
B) Phase I/II Pharmacokinetic Study
C) A large open label safety study conducted at a large number of study sites
D) Phase III pivotal study --CORRECT ANSWER--D) Phase III pivotal study
Your company is developing a product to treat a serious and life threatening
disease. A clinically meaningful, well established primary endpoint will be used
in the pivotal studies. Which regulatory strategy might you select prior to
commencing Phase 3 studies?
Page 4 of 37
